fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Casopitant

Criteria

Inclusion criteria:

• Primary diagnosis of Social Anxiety Disorder.

• Willing to restrict alcohol to a limited intake.

Exclusion criteria:

• History of schizophrenia, schizoaffective disorder or a bipolar disorder.

• Left-handed.

• Suffer from claustrophobia.

• Any reason why subject could not go into the fMRI, for example have metal implants.